Similar articles

• Treatment of Schnitzler's syndrome with anakinra: report of three cases and review of the literature.

  Gran JT, Midtvedt Ø, Haug S, Aukrust P. Gran JT, et al. Scand J Rheumatol. 2011 Jan;40(1):74-9. doi: 10.3109/03009742.2010.493894. Epub 2010 Oct 11. Scand J Rheumatol. 2011. PMID: 20936987 Review. No abstract available.
• [Schnitzler syndrome: A dramatic improvement with anakinra].

  Billey T, Beldjerd M, Popa L, Lassoued S. Billey T, et al. Presse Med. 2010 Dec;39(12):1338-9. doi: 10.1016/j.lpm.2010.07.009. Epub 2010 Sep 15. Presse Med. 2010. PMID: 20832239 French. No abstract available.
• Delayed development of the IgM paraprotein in Schnitzler's syndrome.

  Mulla E, Neame R. Mulla E, et al. Scand J Rheumatol. 2015;44(6):521-2. doi: 10.3109/03009742.2015.1071421. Epub 2015 Sep 23. Scand J Rheumatol. 2015. PMID: 26395927 No abstract available.
• Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory case of Schnitzler's syndrome.

  Kluger N, Rivière S, Guillot B, Bessis D. Kluger N, et al. Acta Derm Venereol. 2008;88(3):287-8. doi: 10.2340/00015555-0404. Acta Derm Venereol. 2008. PMID: 18480937 No abstract available.
• Schnitzler syndrome: response to anakinra in two cases and a review of the literature.

  Schuster C, Kränke B, Aberer E, Arbab E, Sturm G, Aberer W. Schuster C, et al. Int J Dermatol. 2009 Nov;48(11):1190-4. doi: 10.1111/j.1365-4632.2009.04151.x. Int J Dermatol. 2009. PMID: 20064173 Review.